Immunome, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-53.84Mn |
Net Profit Margins | -Inf% |
Immunome, Inc. Common Stock’s revenue fell -100% since last year same period to $0Mn in the Q1 2026. On a quarterly growth basis, Immunome, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Immunome, Inc. Common Stock’s net profit fell -29.3% since last year same period to $-53.84Mn in the Q1 2026. On a quarterly growth basis, Immunome, Inc. Common Stock has generated 22.98% jump in its net profits since last 3-months.
Immunome, Inc. Common Stock’s net profit margin fell -Inf% since last year same period to -Inf% in the Q1 2026. On a quarterly growth basis, Immunome, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -0.51 |
EPS Estimate Current Year | -0.51 |
Immunome, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.51 - a 13.71% jump from last quarter’s estimates.
Immunome, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.51.
Key Ratios
Earning Per Share (EPS) | -0.5 |
Immunome, Inc. Common Stock’s earning per share (EPS) jumped 0% since last year same period to -0.5 in the Q2 2026. This indicates that the Immunome, Inc. Common Stock has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-05-12 | -0.59 | 0 | 100% |
2026-08-12 | -0.51 | -0.5 | 1.96% |
